Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE PHARMACOKINETICS, SAFETY, EFFICACY, AND PHARMACODYNAMICS OF PF-06801591 (PD-1 INHIBITOR) IN PARTICIPANTS WITH ADVANCED MALIGNANCIES

NCT04181788 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04181788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04181788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE PHARMACOKINETICS, SAFETY, EFFICACY, AND PHARMACODYNAMICS OF PF-06801591 (PD-1 INHIBITOR) IN PARTICIPANTS WITH ADVANCED MALIGNANCIES
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Completed
Start date
March 18, 2020
Completion date
May 13, 2026
Enrollment
155 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies, non-small-cell lung cancer